Oncological miR-182-3p, a Novel Smooth Muscle Cell Phenotype Modulator, Evidences From Model Rats and Patients | Zendy

Lan Sun | Zendy; Yongyi Bai | Zendy; Rui Zhao | Zendy; Tao Sun | Zendy; Ruihua Cao | Zendy; Fuyu Wang | Zendy; Guorong He | Zendy; Wen Zhang | Zendy; Ying Chen | Zendy; Ping Ye | Zendy; Guanhua Du | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Oncological miR-182-3p, a Novel Smooth Muscle Cell Phenotype Modulator, Evidences From Model Rats and Patients

Author(s) -

Lan Sun,

Yongyi Bai,

Rui Zhao,

Tao Sun,

Ruihua Cao,

Fuyu Wang,

Guorong He,

Wen Zhang,

Ying Chen,

Ping Ye,

Guanhua Du

Publication year - 2016

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.115.307412

Subject(s) - phenotype , neuroscience , cell , microbiology and biotechnology , cancer research , biology , medicine , chemistry , gene , genetics

Vascular smooth muscle cell (VSMC) phenotype change is a hallmark of vascular remodeling, which contributes to atherosclerotic diseases and can be regulated via microRNA-dependent mechanisms. We recently identified that asymmetrical dimethylarginine positively correlates to vascular remodeling-based diseases. We hypothesized that asymmetrical dimethylarginine induces smooth muscle cell (SMC) phenotypic change via a microRNA-dependent mechanism.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research